Marker Therapeutics (MRKR) Competitors

Lantern Pharma (NASDAQ:LTRN) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Do institutionals & insiders have more ownership in LTRN or MRKR?

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by company insiders. Comparatively, 7.8% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts rate LTRN or MRKR?

Lantern Pharma presently has a consensus price target of $25.00, suggesting a potential upside of 445.85%. Marker Therapeutics has a consensus price target of $13.17, suggesting a potential upside of 944.97%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Marker Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50

Is LTRN or MRKR more profitable?

Lantern Pharma has a net margin of 0.00% compared to Marker Therapeutics' net margin of -224.46%. Lantern Pharma's return on equity of -89.44% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-89.44%	-75.03%
Marker Therapeutics	-224.46%	-101.87%	-83.02%

Does the media refer more to LTRN or MRKR?

In the previous week, Marker Therapeutics had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 4 mentions for Marker Therapeutics and 3 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.57 beat Marker Therapeutics' score of 0.29 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation and earnings, LTRN or MRKR?

Marker Therapeutics has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$20.78M	-$1.84	-2.49
Marker Therapeutics	$6.59M	2.16	-$10.73M	-$1.33	-0.95

Which has more volatility and risk, LTRN or MRKR?

Lantern Pharma has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.

Summary

Marker Therapeutics beats Lantern Pharma on 10 of the 16 factors compared between the two stocks.